Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
LeMaitre Vascular to Present at Upcoming Investor Conferences
-
LeMaitre Vascular to Present at the Canaccord Genuity Annual Growth Conference on Thursday, August 8, 2019
-
LeMaitre Vascular (LMAT) PT Raised to $29 at Canaccord Genuity
-
LeMaitre Vascular (LMAT) PT Raised to $25 at Canaccord Genuity
-
LeMaitre Vascular (LMAT) PT Lowered to $23 at Canaccord Genuity
-
LeMaitre Vascular (LMAT) PT Lowered to $32 at Canaccord Genuity
-
LeMaitre Vascular to Present at Upcoming Investor Conferences
-
LeMaitre Vascular (LMAT) PT Lowered to $31 at Canaccord Genuity
-
LeMaitre Vascular (LMAT) PT Raised to $33 at Canaccord Genuity
-
LeMaitre Vascular to Present at Upcoming Investor Conferences
-
Canaccord Genuity Downgrades LeMaitre Vascular (LMAT) to Hold
-
LeMaitre Vascular to Present at Three Investor Conferences in November
-
LeMaitre Vascular to Participate in the Canaccord Genuity 36th Annual Growth Conference on August 11, 2016
-
Canaccord Genuity Boosts PT on LeMaitre Vascular (LMAT) to $18.50 after 'Credible Road Map' Discussed at Analyst Day
-
LeMaitre Vascular to Present at Four Investor Conferences in November
-
LeMaitre Vascular (LMAT) PT Raised to $16.50 at Canaccord Genuity Following 'Another Outstanding Quarter'
-
LeMaitre Vascular to Present at Three Investor Conferences in August
-
LeMaitre Vascular to Participate in Three Investor Conferences in November 2014
-
LeMaitre Vascular to Present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014
-
LeMaitre Vascular, Inc. Closes Public Offering of Common Shares
-
LeMaitre Vascular (LMAT) Plans Public Offering
-
LeMaitre Vascular, Inc. Announces Proposed Public Offering of Common Stock
-
Canaccord Genuity Maintains a 'Buy' on LeMaitre Vascular (LMAT); Q2 Beats; AlboGraft Back on the Market

